Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19382964 | METHOD FOR MAKING METHANE FROM CARBON DIOXIDE | November 2025 | March 2026 | Allow | 4 | 0 | 0 | No | No |
| 19383003 | METHOD FOR MAKING A BENZIMIDAZOLE | November 2025 | March 2026 | Allow | 4 | 0 | 0 | No | No |
| 19364654 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | October 2025 | February 2026 | Allow | 4 | 1 | 0 | No | No |
| 19357447 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | October 2025 | January 2026 | Allow | 3 | 0 | 0 | No | No |
| 19352234 | SUBSTITUTED HETEROCYCLES AND USES THEREOF | October 2025 | December 2025 | Allow | 2 | 0 | 0 | No | No |
| 19352045 | BENZO NITROGEN-CONTAINING HETEROAROMATIC RING DERIVATIVE AND USE THEREOF IN MEDICINE | October 2025 | December 2025 | Allow | 2 | 0 | 0 | No | No |
| 19327881 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | September 2025 | January 2026 | Allow | 4 | 1 | 0 | Yes | No |
| 19327867 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | September 2025 | March 2026 | Allow | 6 | 1 | 1 | Yes | No |
| 19323422 | PHARMACEUTICAL COMPOSITION FOR KERATOSIS AND USE THEREOF | September 2025 | March 2026 | Allow | 6 | 0 | 1 | Yes | No |
| 19323694 | STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME | September 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19320604 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | September 2025 | February 2026 | Allow | 5 | 1 | 1 | No | No |
| 19319360 | CANNABINOID ANALOGS, FORMULATIONS, AND METHODS OF USE | September 2025 | January 2026 | Allow | 5 | 0 | 1 | Yes | No |
| 19312645 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19312755 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19312786 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19313046 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | February 2026 | Allow | 6 | 1 | 0 | No | No |
| 19313010 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | February 2026 | Allow | 6 | 1 | 0 | No | No |
| 19312656 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | December 2025 | Allow | 3 | 0 | 0 | No | No |
| 19311344 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | August 2025 | January 2026 | Allow | 5 | 1 | 1 | Yes | No |
| 19309448 | 2-DIARYLMETHYL-4-AMINOTETRAHYDROPYRAN DERIVATIVES AND RELATED COMPOUNDS AS ANTICANCER, ANTIINFLAMMATORY, ANTIFIBROTIC AND NEUROPROTECTIVE AGENTS | August 2025 | November 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19308863 | RAS INHIBITORS | August 2025 | December 2025 | Allow | 4 | 1 | 0 | No | No |
| 19308305 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | August 2025 | March 2026 | Allow | 7 | 1 | 1 | Yes | No |
| 19307340 | READY-TO-USE ORAL LIQUID FORMULATION OF CLONIDINE | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19299954 | METHODS OF TREATING IDIOPATHIC PULMONARY FIBROSIS WITH DEUPIRFENIDONE | August 2025 | March 2026 | Allow | 7 | 1 | 0 | No | No |
| 19299588 | CSF-1R INHIBITORS AND METHODS OF USE THEREOF | August 2025 | November 2025 | Allow | 3 | 0 | 0 | No | No |
| 19299605 | PROCESSES OF MAKING CSF-1R INHIBITORS AND METHODS OF USE THEREOF | August 2025 | March 2026 | Allow | 7 | 1 | 1 | No | No |
| 19299240 | COMBINATION THERAPY WITH CLK/DYRK INHIBITORS AND BCL2 INHIBITORS TO TREAT LEUKEMIA | August 2025 | February 2026 | Allow | 6 | 0 | 2 | Yes | No |
| 19296581 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | August 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19295468 | INHIBITION OF GLIAL CELL ACTIVATION | August 2025 | January 2026 | Allow | 6 | 0 | 1 | Yes | No |
| 19293960 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | August 2025 | February 2026 | Allow | 6 | 0 | 1 | No | No |
| 19290944 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | August 2025 | January 2026 | Allow | 5 | 0 | 1 | Yes | No |
| 19287701 | MODULATORS OF TNF-ALPHA ACTIVITY | July 2025 | October 2025 | Allow | 3 | 0 | 0 | No | No |
| 19281069 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | July 2025 | January 2026 | Allow | 6 | 0 | 0 | Yes | No |
| 19279271 | Arterial Application of Low Dose Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Transient Opening | July 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19280031 | IMMUNO-THERAPEUTIC CHEMICAL COMPOSITIONS AND USES THEREOF | July 2025 | December 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19278636 | DOSAGE REGIMENS FOR BENZGALANTAMINE | July 2025 | October 2025 | Allow | 3 | 0 | 0 | No | No |
| 19274703 | RUXOLITINIB FORMULATION FOR REDUCTION OF ITCH IN ATOPIC DERMATITIS | July 2025 | December 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 19274086 | TOPICAL FORMULATION FOR A JAK INHIBITOR | July 2025 | January 2026 | Allow | 6 | 0 | 0 | Yes | No |
| 19274255 | TRICYCLIC DERIVATIVES AND RELATED USES | July 2025 | January 2026 | Allow | 6 | 0 | 1 | Yes | No |
| 19274280 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | July 2025 | February 2026 | Allow | 7 | 1 | 0 | No | No |
| 19271410 | Sapropterin Formulation | July 2025 | March 2026 | Allow | 8 | 1 | 1 | Yes | No |
| 19270230 | Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use Thereof | July 2025 | December 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19268798 | METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS | July 2025 | September 2025 | Allow | 2 | 0 | 0 | No | No |
| 19267357 | STAT6 MODULATORS AND USES THEREOF | July 2025 | February 2026 | Allow | 7 | 1 | 1 | Yes | No |
| 19265483 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | July 2025 | August 2025 | Allow | 2 | 0 | 0 | No | No |
| 19264673 | TREATMENT OF PROSTATE CANCER | July 2025 | September 2025 | Allow | 2 | 0 | 0 | No | No |
| 19263324 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | July 2025 | January 2026 | Allow | 6 | 1 | 0 | No | No |
| 19261393 | COMPOUND, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, SYNTHESIS METHOD THEREFOR AND USE THEREOF | July 2025 | March 2026 | Allow | 8 | 2 | 0 | No | No |
| 19258335 | ROUTE FOR CONSTRUCTING CHIRAL FRAGMENT OF FEZOLINETANT, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | July 2025 | December 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 19254759 | ANDROGEN RECEPTOR PROTACS | June 2025 | December 2025 | Allow | 5 | 0 | 0 | No | No |
| 19256050 | HYDRATE OF VEGFR INHIBITOR, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR | June 2025 | February 2026 | Allow | 7 | 1 | 0 | No | No |
| 19253112 | TREATMENT OF MIGRAINE | June 2025 | February 2026 | Abandon | 8 | 1 | 0 | Yes | No |
| 19252084 | TOPICAL COMPOSITION | June 2025 | January 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19249959 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | June 2025 | October 2025 | Allow | 4 | 1 | 0 | No | No |
| 19247100 | CONJUGATES, THEIR COMPOSITIONS, AND THEIR RELATED METHODS | June 2025 | December 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 19246287 | AMORPHOUS CABOZANTINIB PARTICLES AND USES THEREOF | June 2025 | January 2026 | Allow | 7 | 2 | 0 | No | No |
| 19244143 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | June 2025 | December 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 19242489 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | June 2025 | December 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 19242785 | METHOD OF ERADICATING TICKS THAT ATTACH TO HUMANS USING LOTILANER FORMULATIONS | June 2025 | October 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19240239 | HETEROARYL COMPOUNDS, SOLID FORMS, PREPARATION METHODS AND USES THEREOF | June 2025 | February 2026 | Allow | 8 | 1 | 1 | Yes | No |
| 19238613 | METHOD FOR FORMING AN N-SUBSTITUTED PYRROLE FROM A HEXADIONE WITH A JUICE CATALYST | June 2025 | August 2025 | Allow | 2 | 1 | 0 | No | No |
| 19238297 | Preparation and Application of Deuterated 4-Phenyl-4-Piperidinols | June 2025 | September 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19237389 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | June 2025 | February 2026 | Abandon | 8 | 1 | 0 | No | No |
| 19237465 | MIRDAMETINIB TREATMENT | June 2025 | March 2026 | Abandon | 9 | 1 | 0 | No | No |
| 19237400 | MIRDAMETINIB TREATMENT | June 2025 | March 2026 | Abandon | 9 | 1 | 0 | No | No |
| 19235996 | Carbon-14 Radioisotope-Labeled Flonicamid and Synthesis Method Thereof | June 2025 | October 2025 | Allow | 4 | 1 | 0 | No | No |
| 19236398 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | June 2025 | November 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19231354 | OPHTHALMIC COMPOSITIONS FOR TREATMENT OF OCULAR SURFACE DAMAGE AND SYMPTOMS OF DRYNESS | June 2025 | March 2026 | Abandon | 9 | 1 | 0 | No | No |
| 19231124 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | September 2025 | Allow | 4 | 0 | 0 | No | No |
| 19229649 | 1,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereof | June 2025 | September 2025 | Allow | 3 | 0 | 0 | No | No |
| 19229702 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | January 2026 | Allow | 8 | 1 | 0 | No | No |
| 19228293 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19228565 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19228179 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19225802 | NON-COVALENT MODIFIERS OF AKT1 AND USES THEREOF | June 2025 | December 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19100372 | CRYSTAL FORM OF SPIROCYCLIC AMINE ARYL PHOSPHORUS OXIDE COMPOUND AND PREPARATION METHOD THEREFOR | June 2025 | March 2026 | Allow | 13 | 2 | 0 | No | No |
| 19225991 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | June 2025 | November 2025 | Allow | 5 | 1 | 0 | No | No |
| 19224188 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | May 2025 | January 2026 | Allow | 8 | 1 | 0 | No | No |
| 19223498 | SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF | May 2025 | January 2026 | Allow | 8 | 2 | 1 | Yes | No |
| 19224580 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME | May 2025 | August 2025 | Allow | 3 | 1 | 0 | No | No |
| 19224111 | AQUEOUS BIOCIDAL COMPOSITION | May 2025 | October 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19222062 | N-HETEROCYCLE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | May 2025 | November 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19222910 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | May 2025 | December 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19221260 | USE OF S-BETA-HYDROXYBUTYRATE COMPOUNDS FOR INDUCTION AND MAINTENANCE OF FLOW | May 2025 | September 2025 | Allow | 4 | 1 | 0 | No | No |
| 19218915 | APPLICATION OF GENIPIN BETA-METHYL DERIVATIVE GEN-17 IN PREPARATION OF DRUG FOR PREVENTION AND TREATMENT OF ACUTE SEVERE PNEUMONIA | May 2025 | September 2025 | Allow | 3 | 1 | 0 | No | No |
| 19215938 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | May 2025 | August 2025 | Allow | 3 | 1 | 0 | No | No |
| 19214766 | METHOD FOR PREPARING CYANO SULFONYL FLUORIDE COMPOUNDS | May 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19213047 | CEVIMELINE LIQUID FORMULATIONS | May 2025 | December 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 19213875 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | May 2025 | August 2025 | Allow | 3 | 1 | 0 | No | No |
| 19212445 | COMPOSITIONS AND METHODS FOR TREATMENT OF PERI-IMPLANTITIS AND PERIODONTITIS | May 2025 | August 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19210898 | PHARMACEUTICAL DOSAGE FORMS AND METHODS OF USE | May 2025 | January 2026 | Allow | 8 | 1 | 1 | Yes | No |
| 19210905 | METHOD FOR CARBON DIOXIDE FIXATION USING A PALLADIUM-DOPED NITROGEN-RICH ORGANIC FRAMEWORK CATALYST | May 2025 | August 2025 | Allow | 3 | 1 | 0 | No | No |
| 19209668 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | May 2025 | December 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19207781 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | May 2025 | September 2025 | Allow | 4 | 2 | 0 | No | No |
| 19207816 | STABLE PHARMACEUTICAL COMPOSITIONS OF EDARAVONE | May 2025 | September 2025 | Allow | 5 | 2 | 0 | No | No |
| 19208416 | METHODS OF TREATMENT WITH ELINZANETANT | May 2025 | September 2025 | Allow | 5 | 1 | 0 | No | No |
| 19208335 | METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICS | May 2025 | July 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19206788 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | May 2025 | July 2025 | Allow | 2 | 1 | 0 | No | No |
| 19205807 | SUBSTITUTED 1',2'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,4'-PYRIMIDO[5',4':4,5]PYRROLO[2,1-c][1,2,4]TRIAZIN]-3'-ONES AS CYCLIN-DEPENDENT KINASE INHIBITORS | May 2025 | October 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19204186 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | May 2025 | January 2026 | Allow | 8 | 0 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1620.
With a 30.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1620 is part of Technology Center 1600. This group has examined 178,989 patent applications in our dataset, with an overall allowance rate of 67.6%. Applications typically reach final disposition in approximately 25 months.
Applications in Group 1620 receive an average of 1.54 office actions before reaching final disposition. The median prosecution time is 25 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.